Warning: The NCBI web site requires JavaScript to function. more...
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
Borley AC, Hiscox S, Gee J, Smith C, Shaw V, Barrett-Lee P, Nicholson RI.
Breast Cancer Res. 2008;10(6):R103. Epub 2008 Dec 4.
Related citations
High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW, Martin J, Lynch M.
Br J Cancer. 1990 Apr;61(4):504-7.
Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ.
Br J Cancer. 2004 Nov 1;91(9):1703-10.
Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM, Martin LA, Johnston SR, Ali S, Dowsett M.
J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):333-41.
The anti-proliferative effect of suramin towards tamoxifen-sensitive and resistant human breast cancer cell lines in relation to expression of receptors for epidermal growth factor and insulin-like growth factor-I: growth stimulation in the presence of tamoxifen.
Boylan M, van den Berg HW, Lynch M.
Ann Oncol. 1998 Feb;9(2):205-11.
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Planas-Silva MD, Waltz PK.
J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):11-21. Epub 2007 Jan 2.
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, Gee JM.
Breast Cancer Res Treat. 2010 Jan;119(2):283-93. Epub 2009 Feb 24.
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI.
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. Review.
A molecular strategy to control tamoxifen resistant breast cancer.
Jiang SY, Jordan VC.
Cancer Surv. 1992;14:55-70. Review.
Pure oestrogen antagonists for the treatment of advanced breast cancer.
Howell A.
Endocr Relat Cancer. 2006 Sep;13(3):689-706. Review.
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Martin LA, Pancholi S, Chan CM, Farmer I, Kimberley C, Dowsett M, Johnston SR.
Endocr Relat Cancer. 2005 Dec;12(4):1017-36.
Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M, Fleming FJ, Buggy Y, Hill AD, Young LS.
Endocr Relat Cancer. 2006 Dec;13(4):1135-45.
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.
Breast Cancer Res. 2008;10(6):R104. Epub 2008 Dec 5.
Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.
Hiscox S, Jordan NJ, Jiang W, Harper M, McClelland R, Smith C, Nicholson RI.
Endocr Relat Cancer. 2006 Dec;13(4):1085-99.
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Hiscox S, Jordan NJ, Smith C, James M, Morgan L, Taylor KM, Green TP, Nicholson RI.
Breast Cancer Res Treat. 2009 May;115(1):57-67. Epub 2008 May 21.
Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen.
Bliss RD, Kirby JA, Browell DA, Lennard TW.
Eur J Surg Oncol. 1996 Feb;22(1):27-33.
Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells.
Johnson MD, Westley BR, May FE.
Br J Cancer. 1989 May;59(5):727-38.
Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor.
Masri S, Phung S, Wang X, Wu X, Yuan YC, Wagman L, Chen S.
Cancer Res. 2008 Jun 15;68(12):4910-8.
The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, Toyooka S, Nogami T, Shien T, Doihara H, Miyoshi S.
Breast Cancer Res. 2010;12(3):R43. Epub 2010 Jun 28.
p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.
Fernandez-Cuesta L, Anaganti S, Hainaut P, Olivier M.
Int J Cancer. 2011 Apr 15;128(8):1813-21. doi: 10.1002/ijc.25512.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on